Report of Foreign Issuer (6-k)
June 07 2018 - 3:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2018
Commission File Number
001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrant’s name into English)
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F:
FORM
20-F ☒ FORM
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934:
YES ☐ NO ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b):
On June 7, 2018, Summit Therapeutics plc (the “Company”) issued a press release announcing the
results of the resolutions proposed at the Company’s Annual General Meeting. The related press release is attached hereto as Exhibit 99.1.
The
information in this Report on Form
6-K,
including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
SUMMIT THERAPEUTICS PLC
|
|
|
|
|
By:
|
|
/s/ Erik Ostrowski
|
|
|
|
Erik Ostrowski
Chief Financial Officer
|
Date: June 7, 2018
EXHIBIT INDEX
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
99.1
|
|
Press release dated June 7, 2018
|
Exhibit 99.1
Summit Therapeutics plc
(‘Summit’ or the “’Company’)
Result
of Annual General Meeting
Oxford, UK, and Cambridge, MA, US, 7
June 2018 –
Summit Therapeutics plc (NASDAQ: SMMT, AIM:
SUMM) announces that all resolutions proposed to shareholders at the Company’s Annual General Meeting (‘AGM’) held earlier today have been passed. The results of the proxy votes lodged in advance and at the meeting will be available
shortly from the Investors section of Summit’s website,
www.summitplc.com
.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications in neuromuscular and
infectious diseases for which there are no existing or only inadequate therapies. Summit is currently conducting clinical programmes focused on the neuromuscular disease Duchenne muscular dystrophy and the infectious disease
C. difficile
infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
Contacts
|
|
|
|
|
|
|
Summit
|
|
|
|
|
|
Glyn Edwards
/
Richard Pye (UK office)
|
|
Tel:
|
|
44 (0)1235 443 951
|
|
Erik Ostrowski / Michelle Avery (US office)
|
|
|
|
+1 617 225 4455
|
|
|
|
|
|
Cairn Financial Advisers LLP
(Nominated Adviser)
|
|
Tel:
|
|
+44 (0)20 7213 0880
|
|
Liam Murray / Tony Rawlinson
|
|
|
|
|
|
|
|
|
|
N+1 Singer
(Joint Broker)
|
|
Tel:
|
|
+44 (0)20 7496 3000
|
|
Aubrey Powell / Jen Boorer
|
|
|
|
|
|
|
|
|
|
Panmure Gordon
(Joint Broker)
|
|
Tel:
|
|
+44 (0)20 7886 2500
|
|
Freddy Crossley, Corporate Finance
|
|
|
|
|
|
|
|
|
|
MacDougall Biomedical Communications
(US)
|
|
Tel:
|
|
+1 781 235 3060
|
|
Karen Sharma
|
|
|
|
ksharma@macbiocom.com
|
|
|
|
|
|
Consilium Strategic Communications
(UK)
|
|
Tel:
|
|
+44 (0)20 3709 5700
|
|
Mary-Jane Elliott / Jessica Hodgson /
|
|
|
|
summit@consilium-comms.com
|
|
Lindsey Neville / Philippa Gardner
|
|
|
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024
